Literature DB >> 11873003

HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries?

Dilys Morgan1, Cedric Mahe, Billy Mayanja, J Martin Okongo, Rosemary Lubega, James A G Whitworth.   

Abstract

OBJECTIVES: To describe the progression times of HIV-1 infection from seroconversion to AIDS and to death, and time from first developing AIDS to death in rural Uganda. Also, to describe the proportion of individuals within the cohort dying with AIDS and the CD4 lymphocyte count before death.
DESIGN: A prospective, longitudinal, population-based cohort.
METHODS: Since 1990, 107 HIV-prevalent cases, 168 incident cases and 235 HIV-seronegative controls have been recruited into a cohort in rural Uganda. Participants are recruited from the general population and they are reviewed routinely every 3 months and at other times when ill.
RESULTS: The median time from seroconversion to death was 9.8 years. Age over 40 years at seroconversion was associated with more rapid progression (P < 0.001, log rank test). For the first 4 years of the study, HIV contributed little to the death rates in the HIV incident cases, but after 5 years, the contribution of HIV became greater and was particularly marked in the oldest age group. Survival rates in the cohort were similar to those in the general population. The median time from seroconversion to AIDS was 9.4 years and from AIDS to death was 9.2 months. Of those infected with HIV-1, 80% died with AIDS and 20% had a CD4 count < 10 x 106 cells/l.
CONCLUSIONS: Survival with HIV-1 infection is similar in Africa to industrialized countries before the use of antiretroviral therapy; when they do die, many of those in Africa are severely immunosuppressed and most have clinical features of AIDS.

Entities:  

Mesh:

Year:  2002        PMID: 11873003     DOI: 10.1097/00002030-200203080-00011

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  100 in total

1.  Scaling up circumcision programs in Southern Africa: the potential impact of gender disparities and changes in condom use behaviors on heterosexual HIV transmission.

Authors:  Kyeen M Andersson; Douglas K Owens; A David Paltiel
Journal:  AIDS Behav       Date:  2011-07

2.  More on the cohort-component model of population projection in the context of HIV/AIDS: A Leslie matrix representation and new estimates.

Authors:  Jason R Thomas; Samuel J Clark
Journal:  Demogr Res       Date:  2011-07-05

3.  HIV and population dynamics: a general model and maximum-likelihood standards for east Africa.

Authors:  Patrick Heuveline
Journal:  Demography       Date:  2003-05

Review 4.  Impact of the HIV epidemic on population and household structure: the dynamics and evidence to date.

Authors:  Patrick Heuveline
Journal:  AIDS       Date:  2004-06       Impact factor: 4.177

5.  Computational investigation of the anti-HIV activity of Chinese medicinal formula Three-Huang Powder.

Authors:  Jack Z Hu; Li Bai; Da-Gang Chen; Qi-Tai Xu; William M Southerland
Journal:  Interdiscip Sci       Date:  2010-05-01       Impact factor: 2.233

6.  HIV and cancer in Africa: mutual collaboration between HIV and cancer programs may provide timely research and public health data.

Authors:  Sam M Mbulaiteye; Kishor Bhatia; Clement Adebamowo; Annie J Sasco
Journal:  Infect Agent Cancer       Date:  2011-10-17       Impact factor: 2.965

Review 7.  Measuring trends in prevalence and incidence of HIV infection in countries with generalised epidemics.

Authors:  P D Ghys; E Kufa; M V George
Journal:  Sex Transm Infect       Date:  2006-04       Impact factor: 3.519

8.  HIV epidemic trend and antiretroviral treatment need in Karonga District, Malawi.

Authors:  R G White; E Vynnycky; J R Glynn; A C Crampin; A Jahn; F Mwaungulu; O Mwanyongo; H Jabu; H Phiri; N McGrath; B Zaba; P E M Fine
Journal:  Epidemiol Infect       Date:  2007-01-12       Impact factor: 2.451

9.  Behaviour change and competitive exclusion can explain the diverging HIV-1 and HIV-2 prevalence trends in Guinea-Bissau.

Authors:  W P Schmidt; M Schim Van Der Loeff; P Aaby; H Whittle; R Bakker; M Buckner; F Dias; R G White
Journal:  Epidemiol Infect       Date:  2007-06-11       Impact factor: 2.451

10.  Endpoints and regulatory issues in HIV vaccine clinical trials: lessons from a workshop.

Authors:  Dean Follmann; Ann Duerr; Stephen Tabet; Peter Gilbert; Zoe Moodie; Patricia Fast; Massimo Cardinali; Steve Self
Journal:  J Acquir Immune Defic Syndr       Date:  2007-01-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.